The Scroggins laboratory employs innovative approaches and designs in our studies, utilizing state-of-the-art single-cell and multiomic techniques alongside preclinical animal models and human research across all endeavors. We focus on understanding how hypertensive disorders during pregnancy impact the immediate and long-term development of immunological, cardiovascular, and central nervous system disorders in both mothers and their babies. Our goal is to uncover the underlying mechanisms of these diseases to develop innovative strategies for treating current conditions and preventing future ones in both mother and child. Several projects in our lab are dedicated to these areas of research.
Hypertensive disorders during pregnancy are linked to heightened risks of subsequent immunological, cardiovascular, and neurocognitive disorders for both mother and child. Our investigations seek to unravel the maternal and fetal immunological, vascular, and central nervous system alterations induced by hypertensive disorders of pregnancy, encompassing both immediate and long-term developmental changes in both maternal and fetal contexts.
Throughout pregnancy, maternal cells migrate into the fetus, while fetal cells traverse into the maternal circulation, a phenomenon known as microchimerism. These cells, predominantly immune cells, have been observed to persist in various tissues for decades. Our laboratory is intrigued by the impact of these cells on future cardiovascular, immunological, and central nervous system health of both mother and child.
Hypertensive disorders of pregnancy affect around 21 million pregnancies annually and are a leading cause of maternal and infant mortality worldwide. Currently, the only cure is delivering the placenta and fetus, often leading to preterm birth and increased fetal risks. Contributing factors include maternal intolerance to the fetus and inflammatory mechanisms. Our research aims to uncover the immune mechanisms behind these disorders to develop new therapies. Recent progress in preclinical animal models shows promise with cellular immunotherapy, and we are now working to translate these findings to human treatments.
